Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 10/2015

Open Access 01-10-2015 | Review

Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement

Authors: Alberto Albanese, Giovanni Abbruzzese, Dirk Dressler, Wojciech Duzynski, Svetlana Khatkova, Maria Jose Marti, Pablo Mir, Cesare Montecucco, Elena Moro, Michaela Pinter, Maja Relja, Emmanuel Roze, Inger Marie Skogseid, Sofiya Timerbaeva, Charalampos Tzoulis

Published in: Journal of Neurology | Issue 10/2015

Login to get access

Abstract

Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients’ self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information.
Literature
1.
Charles PD, Adler CH, Stay M et al (2014) Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 261:13019–13098CrossRef
2.
Camfield L, Ben-Shlomo T, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838–841CrossRefPubMed
3.
Jankovic J, Adler CH, Charles PD et al (2011) Rational and design of a prospective study: cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurology 11:140PubMedCentralCrossRefPubMed
4.
Swope D, Barbano R (2008) Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 26(Suppl 1):54–65CrossRefPubMed
5.
Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18CrossRefPubMed
6.
Simpson DM, Blitzer A, Brashear A (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1699–1706CrossRefPubMed
7.
Murphy MK, Black NA, Lamping DL et al (1998) Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2(no 3):1–88
8.
9.
Tassorelli C, Mancini F, Balloni L et al (2006) Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 21:2240–2243CrossRefPubMed
10.
Volkmann J, Mueller J, Deuschl G et al (2014) DBS study group for dystonia. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 13(9):875–884. doi:10.​1016/​S1474-4422(14)70143-7 (Epub 2014 Aug 7)CrossRefPubMed
11.
12.
Albanese A, Barnes MP, Bhatia KP et al (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES task force. Eur J Neurol 13:433–444CrossRefPubMed
13.
Colosimo C, Supa A, Fabbrini G et al (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15–21CrossRefPubMed
14.
Zoons E, Dijkgraaf MGW, Dijk JM et al (2012) Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 259:2519–2526PubMedCentralCrossRefPubMed
15.
Dressler D, Rothwell JC (2000) Electromyograpjc quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43(1):13–16CrossRefPubMed
16.
Meija NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592–597CrossRef
17.
Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265–273CrossRefPubMed
18.
Truong D (2012) Botulinum toxins in the treatment of primary focal dystonias. J Neurolog Sci 316:9–14CrossRef
19.
Jankovic J, Leder S, Warner D, Schwartz K (1991) Cervical dystonia: clinical findings and associated movement disorders. Neurology 41:1088–1091CrossRefPubMed
20.
Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163–170CrossRefPubMed
21.
Skogseid IM, Røislien J (2005) Claussen, Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604–1609CrossRefPubMed
22.
Bove M, Brichetto G, Abbruzzese G, Marchese R, Schieppate M (2004) Neck proprioception and spatial orientation in cervical dystonia. Brain 127(Pt 12):2764–2778CrossRefPubMed
23.
Pelosin E, Bove M, Marinelli L, Abbruzzese G, Ghilardi MF (2009) Cervical dystonia affects aimed movements of nonodystonic segments. Mov Disord 24(13):1955–1961CrossRefPubMed
24.
Stamelou M, Edwards MJ, Hallett M, Bhatia KP (2012) The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain 135:1668–1681PubMedCentralCrossRefPubMed
25.
Comella CL, Stebbins GT, Miller S (1996) Specific dystonic factors contributing to work limitation and disability in cervical dystonia. Neurology 46(Suppl 2):A259
26.
Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23–42CrossRefPubMed
27.
Skogseid IM, Malt UF, Røislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129–1137CrossRefPubMed
28.
Slawek J, Friedman A, Potulska A et al (2007) Factors affecting health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95–100PubMed
29.
30.
Ben-Shlomo Y, Camfield L, Warner T, ESDE collaborative group (2002) what are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608–614PubMedCentralCrossRefPubMed
31.
Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:1–5CrossRef
32.
33.
34.
Lalli S, Albanese A (2010) The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 25(11):1619–1626CrossRefPubMed
35.
Moore P, Naumann M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of botulinum toxin treatment, 2nd edn. Blackwell Science, Oxford
36.
37.
Dressler D, Kupsch A, Seitzinger A, Paus S (2014) The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol. doi:10.​1111/​ene.​12330
38.
Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5–12CrossRef
39.
Flowers JM, Hicklin LA, Marion M-H (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26(13):2409–2414. doi:10.​1002/​mds.​23905 CrossRefPubMed
40.
Dressler D (2000) Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7(6):713–718CrossRefPubMed
41.
Lim ECH, Quek AML, Seet RCS (2012) Accurate targeting of botulinum toxin injections: how to and why. Parkinson Rel Dis 17:S34–S39CrossRef
42.
43.
44.
45.
46.
Bentovglio AR, Bagella CF, Albanese A (2015) Botulinum toxin in movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson’s disease & Movement Disorders, 6th edn. Wolters Kluver, Philadelphia, pp. 480–495
47.
48.
Greene P, Kang U, Fahn S et al (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213–1218CrossRefPubMed
49.
Misra VP, Ehler E (2012) Zakine B et al Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2:e000881PubMedCentralCrossRefPubMed
50.
Dressler D, Tacik P, Adib Saberi F (2015) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122(2):297–300CrossRefPubMed
51.
Evidente VGH, Fernandez HH, LeDoux MS et al (2013) A randomized, double-blind study of repeated incobotulinum toxinA (Xeomin®) in cervical dystonia. J Neural Trans 120(12):1699–1707CrossRef
52.
Comella CL, Jankovic J, Truong DD et al (2011) Efficacy and safety of incobotulinumtoxin A (NT 201, Xeomin® botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 208:103–109CrossRef
53.
Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981–990CrossRefPubMed
54.
Borodic GE, Joseph M, Fay L et al (1990) Botulinum toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12:392–399CrossRefPubMed
55.
Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum-A-toxin injection. Mov Disord 9:31–39CrossRefPubMed
56.
Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxinA. Arch Dermatol 140:1351–1354CrossRefPubMed
57.
Carli L, Montecucco C, Rossatto O (2009) Assay of diffusion of different botulinum toxin type a formulations. Musc Nerve 40:374–380CrossRef
58.
Tang-Liu DD, Aoki KR, Dolly JO et al (2003) Intramuscular injection of 125I- botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42:461–469CrossRefPubMed
59.
Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics Targets Ther 10:325–332CrossRef
60.
Benecke R, Moore P, Dressler D, Nauman M (2003) Cervical and axial dystonia. In: Moore P, Nauman M (eds) Handbook of botulinum toxin treatment, chap 8, 2nd edn. Blackwell Science, Oxford
61.
Aranda MA, Herranz A, del Val J, Belido S, Garcia-Ruiz P (2012) Botulinum toxin A during pregnancy, still a debate. Eur J Eurol 19:e81–e82CrossRef
62.
Brin MF, Comella CL, Jankovic J et al (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low antigenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRefPubMed
63.
Dressler D (1997) Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 4(suppl 2):S67–S70
64.
Ferreria JJ, Bhidayasiri R, Colosimo C et al (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27(4):225–230
65.
Jost WH, Blumel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 67:669–683CrossRefPubMed
66.
Cordivari C, Misra VP, Vincent A et al (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737–1741CrossRefPubMed
67.
68.
Walsh RA, Sidiropoulos C, Lozano AM et al (2013) Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 136:761–769CrossRefPubMed
69.
Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255(12):1932–1939CrossRefPubMed
70.
Marchetti A, Magar R et al (2005) Retrospective Evaluation of the Dose of Dysport and BOTOX in the Management of Cervical Dystonia and Blepharospasm: The REAL DOSE Study. Mov Disord 20(8):937–944CrossRefPubMed
71.
Wohlfarth K, Sycha T, Ranoux D et al (2009) Dose equivalence in two preparations of botulinum toxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584CrossRefPubMed
72.
Grosset DG, Tyrrell EG, Grosset KA (2013) Conversion from Dysport® to Xeomin® formulation of botulinum toxin: clinical experience in 257 cases. Botulinum J 2(3/4):276
73.
Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxin A (Botox®) and incobotulinumtoxin A (Xeomin®). J Neural Trans 121:29–31CrossRef
74.
Odergren T, Hjaltason H (1998) Kaakkola S et al A double-blind randomised, parallel-group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatr 64:6–12PubMedCentralCrossRefPubMed
75.
Bihari K (2005) Safety, effectiveness and duration of effect of BOTOX compared with Dysport for blepharospasm, cervical dystonia and hemifacial spasm. Curr Med Res Opin 21(3):433–438CrossRefPubMed
76.
Ranoux D et al (2002) Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462PubMedCentralPubMed
77.
Chapman MA, Barron R, Tanis DC et al (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325–1337CrossRefPubMed
78.
Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharm 32:28–31CrossRef
79.
Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT201) compared with commercially available boutlinum toxin type A (BOTOX®) in healthy volunteers. J Neural Transm 112:905–913CrossRefPubMed
80.
Benecke R, Jost WH, Kanovsky P et al (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951CrossRefPubMed
81.
Roggenkämper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Trans 113:303–312CrossRef
82.
Dressler D (2009) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2–5CrossRefPubMed
83.
84.
Benecke R, Hauschke D (2013) IncobotulinumtoxinA demonstrated equivalent efficacy to onabotulinumtoxinA in the treatment of cervical dystonia. Botulinum J 2(3/4):217
85.
Lowe NJ, Yamauchi PS, Lask GP et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experience with type B toxin dosing. J Cosmet Laser Ther 4:15–18CrossRefPubMed
86.
Blitzer A (2005) Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head and Neck Surg 133:836–838CrossRef
87.
Kranz G, Paul A, Voller B et al (2011) Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol 164:176–181CrossRefPubMed
88.
Poewe W, Deuschl G, Nebe A et al (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double-blind placebo controlled dose ranging study of Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64:13–17PubMedCentralCrossRefPubMed
89.
Truong D, Duane DD, Jankovic J et al (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomised, double-blind, placebo-controlled study. Mov Disord 20:783–791CrossRefPubMed
90.
Truong DD, Brodsky M (2010) Lew M et al Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316–323CrossRefPubMed
91.
Brans JW, Lindeboom R (1996) Snoek JW et al Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066–1072CrossRefPubMed
92.
Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23:510–517CrossRefPubMed
93.
Comella CL, Jankovic J, Shannon KM, Dystonia Study Group et al (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423–1429CrossRefPubMed
94.
Novak Campbell L, Boyce M, Fung VSC (2010) Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 17(Suppl 2):94–108CrossRefPubMed
Metadata
Title
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
Authors
Alberto Albanese
Giovanni Abbruzzese
Dirk Dressler
Wojciech Duzynski
Svetlana Khatkova
Maria Jose Marti
Pablo Mir
Cesare Montecucco
Elena Moro
Michaela Pinter
Maja Relja
Emmanuel Roze
Inger Marie Skogseid
Sofiya Timerbaeva
Charalampos Tzoulis
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 10/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7703-x

Other articles of this Issue 10/2015

Journal of Neurology 10/2015 Go to the issue

Original Communication

Deep brain stimulation and cognitive decline in Parkinson’s disease: The predictive value of electroencephalography

Original Communication

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

Original Communication

A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family

Original Communication

Resting-state functional connectivity of dentate nucleus is associated with tremor in Parkinson’s disease

Original Communication

Relevance of hippocampal integrity for memory outcome after surgical treatment of mesial temporal lobe epilepsy

Journal club

Refining the phenotype of inborn errors of metabolism